Long-term immunogenicity of a plasma-derived hepatitis B vaccine in HIV seropositive and HIV seronegative hemophiliacs

P. M. Mannucci, A. R. Zanetti, A. Gringeri, E. Tanzi, M. Morfini, A. Messori, M. C. Tirindelli, R. De Biasi, N. Ciavarella, M. Colombo

Research output: Contribution to journalArticlepeer-review


Short-term studies indicate that hepatitis B vaccines are safe and satisfactory immunogenic in hemophiliacs. The duration of immunity in these immunocompromised patients, however, is not known. To determine this, we studied 78 hemophiliacs prospectively 2,3 and 4 years after the initial vaccination with a plasma-derived vaccine given as three monthly injections followed by a fourth booster injection at month 14. The duration of immunity clearly depended on whether the patients were infected with the human immunodeficiency virus (HIV). In HIV seronegative hemophiliacs (n = 67), there was a progressive decline in titers of antibody to the hepatitis B surface antigen (anti-HBs), but antibody was still detectable 4 years later in all of them. From the curves of decline of antibody titers, it appears that there is no need to revaccinate patients for at least 5 to 6 years. The HIV seropositive hemophiliacs (n = 11) not only started from much lower anti-HBs titers, but 5 of 11 lost anti-HBs. None of the 45 patients treated with concentrates during the postvaccination period developed serologic signs of hepatitis B, even though 6 of them had come into contact with live or inactivated hepatitis B virus as shown by the occurrence of spontaneous anamnestic antibody responses. This vaccine and schedule of vaccination afford a prolonged duration of immunity in HIV seronegative hemophiliacs, but HIV seropositive hemophiliacs have a risk of losing immunity early.

Original languageEnglish
Pages (from-to)1333-1337
Number of pages5
JournalArchives of Internal Medicine
Issue number6
Publication statusPublished - 1989

ASJC Scopus subject areas

  • Internal Medicine


Dive into the research topics of 'Long-term immunogenicity of a plasma-derived hepatitis B vaccine in HIV seropositive and HIV seronegative hemophiliacs'. Together they form a unique fingerprint.

Cite this